In the final feature of Big4Bio’s Company to Watch program for July, we asked Meissa Vaccines’ Board Chairperson Kenneth J. Kelley about his predictions for Meissa and the importance of the company’s efforts. Briefly, tell me how you came to chair Meissa Vaccines’ Board of Directors. Marty Moore reached out to me first for advice […]

Company to Watch – Meissa Vaccines As part of July’s Company to Watch program, we spoke to Marty Moore, founder and CEO of Meissa Vaccines, about Meissa’s platform technology, how it works, and why its approach could provide significant benefits over existing COVID-19 vaccine.   NEXT: A Q&A with Ken Kelley, Chairperson of the Board […]

In the second of four features on Meissa Vaccines, Big4Bio explores the company’s technology and pipeline. Company to Watch – Meissa Vaccines When Marty Moore, Meissa Vaccines’ cofounder and CEO, is asked about why the company is advancing an intranasal recombinant live attenuated vaccine for COVID-19, he talks about the oral polio vaccine. Many remember […]

In the first of four features on Meissa Vaccines, Big4Bio spoke with Meissa Vaccines CEO Marty Moore about Meissa’s drive to deliver vaccines against respiratory infections, the technology behind their pipeline, its relevance in today’s post-pandemic world, and what the future holds for the company. Company to Watch – Meissa Vaccines Marie Daghlian Meissa Vaccines […]

THE COMPANY/THE MISSION Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges Meissa Vaccines is on a mission to solve a puzzle that has eluded scientists for decades—a pediatric vaccine against respiratory syncytial virus, or RSV.     THE PIPELINE Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV Making vaccines […]